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Objective: To investigate the use of intraoperative ultrasound during stage I
InterStim® sacral lead placement.
Methods: A total of 40 patients were randomly assigned to undergo InterStim® lead
placement utilizing fluoroscopy or ultrasound guidance. Patients were blinded for the
duration of the study. The surgeon and staff were blinded until after induction of
anesthesia. Patients met criteria for refractory overactive bladder, fecal incontinence, or
both. The ICIQ-OABqol, OABSS, and FIQL validated questionnaires were used pre-
andpost-operatively. Primary endpointwas total fluoroscopy time. Secondary endpoints
were total radiation exposure and total number of foramen needle skin punctures.
Results: Forty patients were enrolled, twenty in the ultrasound and twenty in the
fluoroscopy only arm. Mean age was 60 (SD=14.4) and mean BMI 32 (SD=7.2).
Twenty-seven patients (67.5%) had urinary symptoms, four (10%) fecal incontinence, and
nine (22.5%) had mixed symptoms. Radiation exposure time was reduced by 70.5 s
(P=0.002), radiation exposure was decreased by 42.3mGy (P=0.017), and the number
of needle skin punctures decreased by 3.6 (P=0.035) with use of ultrasound. Mean OR
time in minutes was 55.5 in ultrasound and 58.2 in fluoroscopy group (P=0.53). There
were no statistically significant differences in questionnaire scores between groups.
Conclusion: Ultrasound guided placement of foramen needle during Stage I sacral
neuromodulation results in reduction of radiation exposure to the patient, surgeon,
and operating room staff. Further studies are necessary to determine the learning
curve and efficacy of this technique.
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1 | INTRODUCTION
Overactive bladder (OAB) is defined by the International
Continence Society as “urgency, with or without urge
incontinence, usually with frequency, and nocturia in the
absence of urinary tract infection or other obvious pathol-
ogy.”1 This constellation of symptoms is also known as
overactive bladder syndrome, urge syndrome, or urgency-
frequency syndrome.
TheAmericanUrologicalAssociation created guidelines for
the treatment of OAB. The algorithm is divided into three main
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treatment lines: behavior modification, pharmacology, and
procedural options. The AUA OAB Guideline is the currently
accepted standard of care for the treatment of OAB. Third line
therapies are for patients whose symptoms are refractory to first
and second line therapies. These options include intradetrusor
onabotulinumtoxinA (Botox) injections, peripheral tibial nerve
stimulation/modulation (PTNS/PTNM), or sacral neuromodu-
lation (SNM).2 Patients receiving Botox must be willing and
able to return for post-void residual evaluation and perform
clean intermittent self-catheterization. Patients who choose
PTNS/PTNM must return for weekly treatments for several
months and then ongoing maintenance treatments. SNM
requires a surgical procedure for selected patients after
evaluation prior to moving onto long-term therapy.
SNM was first FDA approved for urge incontinence in
1997 and its use expanded for urgency-frequency and non-
obstructive urinary retention in 1999. InterStim® (Medtronic,
Minneapolis, MN) is the only commercially available device
in this treatment category. InterStim® is also indicated for the
treatment of fecal incontinence since 2011.
SNM functions by placing a stimulating electrode near the
3rd sacral nerve root (S3). The proposed mechanism of action
is that stimulation of somatic sensory afferent pathways alters
voiding reflexes tomodulate bladder and pelvic floor function.
SNM has the advantage of evaluation before placement of
long-term implant. The evaluation can be done with a
temporary lead placement in the office, also known as
peripheral nerve evaluation (PNE). The evaluation phase
may be performed by placing a permanent lead in an outpatient
surgical setting under a short intravenous sedation (stage I).
Detailed bladder diaries and/or bowel diaries along with
patient satisfaction are reviewed to determine success. The
patient must show at least 50% improvement per objective
measures in one ormore bladder or bowel symptomcategories.
If satisfactory objective and subjective results are seen, then the
patient can proceed to permanent InterStim implant.3
Current lead placement techniques are based on identifying
palpable and fluoroscopic anatomic bony landmarks. Measure-
ments based on bony landmarks, as recommended by the
manufacturer, are used during office “blind” PNE technique.
The use of fluoroscopy in the operating room setting allows for
more precise measurements and is currently essential for
permanent leadplacement.4,5Theuseofpalpablebony landmark
measurements is based on normal anatomy without consider-
ation for anatomic or pathologic variations. This may lead to
improper placement of “blind” leads in an office setting and
eventual failure of PNE. Fluoroscopy can confirm placement by
single shot or continuous/live x-ray use, but use of fluoroscopy
may lead to significant radiation exposure to both patient,
surgeon, and operating room staff. In addition, some patients
maybeexposed tomultiple needle entries during attempts to find
the best placement of foramen needle.Multiple needle punctures
may lead to post-operative pain and discomfort.
To our knowledge the use of intra-operative ultrasound
for placement of the foramen needle has not been extensively
explored.We believe ultrasound use may significantly reduce
fluoroscopy time and exposure during lead placement.
The purpose of the study is to compare outcomes of
ultrasound versus fluoroscopically guided placement of sacral
neuromodulation foramen needles. We hypothesize that
ultrasound guided placement will significantly reduce fluoros-
copy time and produce equivalent patient symptom control.
Primary endpoint is fluoroscopy time collected at the
conclusion of the procedure. Secondary endpoints are radiation
exposure in mGy as recorded by the C-arm and patient quality
of life scores collected via validated questionnaires.
2 | MATERIALS AND METHODS
Our study is a prospective randomized blinded trial in which
patients were selected based on the May 2014 AUA OAB
guidelines after exhausting first and second line therapies
including behavior modification, biofeedback, pelvic floor
muscle training, and pharmacologic therapies. We also
included patients with primary fecal incontinence or a
combination of fecal and urinary symptoms. As this was a
pilot study without any previous papers evaluating this
outcome, we elected to start with a sample size of forty based
on our statistician's recommendations. We planned on
expanding our enrollment if needed after the data for the
initial forty patients had been analyzed. Patientswere recruited
from April 2015 until December 2015. Enrolled patients met
all inclusion criteria and none of the exclusion criteria
(Table 1). The research protocol was approved by our
institutional review board and all participants gave written
informed consent prior to initiation into the study. The
study was registered with ISRCTN (trial identifier:
ISRCTN37385347). All procedures were performed in a
community hospital setting. After 50% enrollment, a safety
review was performed which did not reveal any adverse
events. All participants filled out bladder and/or bowel diaries
prior to implantation as is the standard at our institution.
Quality of life questionnaires were also administered pre-
operatively to all patients for bladder dysfunction, bowel
dysfunction, or both. The validated International Consultation
on Incontinence Modular Questionnaire Overactive Bladder
Symptoms Quality of Life (ICIQ-OABqol), as well as the
Overactive Bladder Symptom Score (OABSS) was given to
patients with urinary symptoms.6,7 Patients with fecal
incontinence completed the validated Fecal Incontinence
Quality of Life Scale (FIQL).8 Questionnaires were again
administered at the post-operative visits.
Subjects were randomized using computer-generated
sequence. The randomization order was concealed in sealed,
consecutively numbered envelopes. Patients were blinded to
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the use of ultrasound versus fluoroscopy only and the surgeon
was blinded until the patient was prepped and draped on the
operating room table. No additional changes to our current
institutional protocol on InterStim placement were made. All
patients received prophylactic antibiotics, IV sedation, local
anesthesia, and standard sterile technique. All procedures
were performed by a single high volume fellowship trained
surgeon with assistance by a senior resident with significant
prior InterStim training.
The curved stylet and techniques as described by Siegel
et al4 and Jacobs et al9 were employed. Fluoroscopy is used to
identify the medial aspect of sacral foramina bilaterally in AP
position. Depth and angle adjustments were made with
fluoroscopy in lateral position. Continuous live fluoroscopy is
also used for placement of the lead introducer as well as the
lead itself. Final AP and lateral images are obtained following
deployment of the lead. The primary surgeon and a senior
resident who underwent a one day simulation on use of the
SonoSite S-Nerve™ (FujiFilm Sonosite, Inc., Bothell, WA)
performed all of the procedures. In the ultrasound arm the
SonoSite along with a 13-8MHz linear probe was used to
identify the S3 foramina and place the foramen needle under
ultrasound guidance obviating the need for fluoroscopy
(Figure 1). Fluoroscopy was used for the remainder of the
procedure as described above.
Data recorded included patient demographics, pertinent
medical history (Table 2), pre- and post-operative question-
naire results, number of initial separate needle foramen skin
TABLE 1 Inclusion and exclusion criteria
Inclusion criteria
Diagnosis of overactive bladder, non-obstructive urinary retention,
fecal incontinence, or mixed symptoms
Male or female and 18 years of age or older
Failure of previous conservative measures (ie, behavior
modification, biofeedback, pelvic floor training, at least one
antimuscarinic or beta-agonist medication)
Medically fit to undergo proposed surgery
Patient able to consent
Exclusion criteria
Pregnant or planning on becoming pregnant
Severe or uncontrolled diabetes with peripheral nerve involvement
Knowledge of planned MRI or other procedures precluding
implantation of device or need for removal
Severe BPH, prostate cancer, urethral stricture, or other mechanical
obstruction
Active urinary tract, skin, or soft tissue infection
FIGURE 1 Ultrasound view in the transverse plane identifying S4 foramina (A). Once this landmark has been identified, the probe is shifted
laterally, toward the desired testing site and turned in the sagittal plane to identify the S3 foramen (B)
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punctures, total fluoroscopy time, total radiation exposure in
mGy, and pertinent post-operative data including any
complications (Table 3).
Data was analyzed using means and standard deviations
for continuous variables. Means were compared using
ANOVA analysis. Categorical variables were further exam-
ined using Pearson Fisher's Exact tests. Statistical analysis
was performed by an experienced statistician.
3 | RESULTS
Forty patients were consented, twenty in the ultrasound arm
and twenty in the fluoroscopy arm. A total of five males (one
in ultrasound and four in fluoroscopy arm) and thirty-five
females (19 in ultrasound and 16 in fluoroscopy arm) were
enrolled.Mean agewas 60 (SD = 14.4) andmean BMIwas 32
(SD = 7.2). Fifteen patients had a prior hysterectomy (six in
ultrasound and nine in fluoroscopy arm) and twenty-eight
patients were menopausal (15 in ultrasound and 13 in
fluoroscopy arm). Indications for surgery were pure urinary
symptoms in twenty-seven (15 in ultrasound and 12 in
fluoroscopy arm), pure fecal symptoms in four (two in
ultrasound and two in fluoroscopy arm), andmixed symptoms
in nine (three in ultrasound and six in fluoroscopy arm). None
of the patients had primary urinary retention. Twenty-two
patients had a successful office PNE trial (10 in ultrasound
and 12 in fluoroscopy arm). Eighteen patients refused an
office PNE trial due to concern for discomfort and elected to
have a stage I trial in the operating room under anesthesia.
All patients completed pre- and post-operative question-
naires based on their symptoms. Mean pre-operative ICIQ-
OABqol score was 107.4 (SD = 27.5), bother score 8
(SD = 2.3), OABSS 11.44 (SD = 3.1), and FI-qol 46.6
(SD = 13.8). Mean fluoroscopy time in all groups was
108.4 s (SD = 75.1), mean radiation exposure in mGy was
44.2 (SD = 52.9), and mean number of skin punctures with
foramen needle was 10.4 (SD = 5.5). All group means were
compared using ANOVA.
There was no statistical difference in the demographic
distribution between the two groups, nor was there any
statistical significance in group co-morbidities and pre- and
post-op questionnaire data (Tables 2 and 3). Figure 2A-C
shows a significant reduction in fluoroscopy time (72.9 s vs
143.8 sec, P= 0.002), radiation exposure in mGy (24.3 vs
66.6, P= 0.017), and the number of skin punctures with the
foramen needle during the initial step of the procedure in the
ultrasound group (8.6 vs 12.3, P= 0.035), respectively.
TABLE 2 Demographics and medical history
Demographic
Ultrasound
(n= 20)
Fluoroscopy
(n= 20)
Gender
Male 1 (5%) 4 (20%)
Female 19 (95%) 16 (80%)
Primary diagnosis
Urinary 15 (75%) 12 (60%)
Fecal 2 (10%) 2 (10%)
Mixed 3 (15%) 6 (30%)
Medications tried
1 8 (40%) 8 (40%)
2 8 (40%) 7 (35%)
3 3 (15%) 2 (10%)
>3 1 (5%) 3 (15%)
Number pads per day N= 13 N= 12
1-2 5 (25%) 4 (20%)
3-5 3 (15%) 8 (40%)
>5 5 (25%) 0
Mean age at surgery 60 61
Mean BMI 32 32
Office PNE prior to
OR
10 (50%) 12 (60%)
Diabetes 2 (10%) 4 (20%)
Hysterectomy 6 (30%) 9 (45%)
Menopausal 15 (75%) 13 (65%)
TABLE 3 Results
Ultrasound
(n= 20)
Fluoroscopy
(n= 20) P-value
Mean radiation
mGy 0.017
Seconds 24.3 66.6 0.002
72.9 143.8
Mean skin
punctures
8.6 12.2 0.035
Mean questionnaire score
OABSS
Pre-op 11.4 10.6 0.40
Post-op 5.2 6.9 0.24
ICIQ-OABqol
Pre-op 107.3 102.0 0.54
Post-op 52.2 63.6 0.28
Bother score
Pre-op 8.0 7.7 0.73
Post-op 3.3 4.6 0.25
FI-qol
Pre-op 46.6 57.1 0.15
Post-op 66.8 84.2 0.16
Mean OR time
(min)
55.5 58.2 0.53
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Figure 2D shows no significant difference in total operating
time between the two groups.
4 | DISCUSSION
Increase in medical radiation exposure has been well
documented in recent years. There has been a growing
concern over the long term sequelae of liberate use of various
imaging modalities to patients and medical staff.10 Determin-
istic and stochastic effects of radiation are well characterized
and alternative imaging modalities such as ultrasound have
been suggested in various urologic procedures.11,12 Sacral
neuromodulation has gained wide acceptance as an effective
third line treatment modality for OAB.13 Implantation of this
device relies on fluoroscopy and may increase the overall
radiation burden to patients and medical personnel.
Sacral neuromodulation with the InterStim device has
been deemed an effective treatment modality in refractory
urinary and bowel dysfunction.1,3,14–16 There have beenmany
advances in the device since its inception. One of the most
recent advances includes the use of a curved stylet to mimic
the anatomic trajectory of the sacral nerve root, a technique
employed at our institution.9 The development of a Bluetooth
enabled programmer has simplified adjustments and evalua-
tion of the device.
Traditionally, fluoroscopy has been used in the operating
room setting to aid with lead placement. In our experience,
the majority of fluoroscopy time is devoted to initial
foramen needle placement. Although adequate motor and
sensory response may be elicited with the foramen needle,
one has to plan for and understand the trajectory of the lead,
which if deployed at a suboptimal angle may not reproduce
responses at low amplitudes at all four electrodes of the
tined lead.17 Therefore, our group spends more time during
this step of the procedure to ensure optimal results when the
lead is introduced.18 We routinely reposition the foramen
needle and lead to obtain motor responses at amplitude of
<1. Our OR time may therefore be longer than that
FIGURE 2 Comparison of fluoroscopy time (A) radiation exposure in milligray (B) the number of initial skin punctures with the foramen
needle (C) and total operating time (D) between ultrasound (1) and fluoroscopy (2) groups
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experienced by other groups. Anatomic landmarks using
ultrasound have been developed as illustrated in Figure 1.
By using ultrasound we were able to safely guide the
foramen needle into the S3 foramen and reduced our
radiation exposure time by an average of 70.5 s (P= 0.002).
We elected to report radiation exposure in mGy as this is
tracked at our institution for all fluoroscopic procedures and
could easily be tracked in future studies. The mean decrease
in radiation exposure as measured in mGy was 42.3
(P= 0.017). Initial needle punctures to find the foramen
was also reduced using the ultrasound technique
(P= 0.035), although the clinical significance of this metric
is debatable as we did not power our study to see any
difference in pain or infection parameters between the two
groups.
The use of validated questionnaires in our cohorts
demonstrated equivalent symptomatic relief in both groups
and produced no statistical significance in quality of life
outcomes. Infection of the device has been reported between
3% and 10%.19 We did not experience any complications
due to infections in our cohort. This may be due to our
judicious use of antibiotics pre- and post-operatively,
especially in at risk patients. Intra-operative motor and
sensory response can be used concurrently to determine
appropriate placement. Motor response rate has been shown
to be a better predictor of positive outcome and we elect to
use motor response at low threshold values (<1) for the
majority of our patients.20
Our study is the first to explore a novel technique in
SNM and demonstrate a reduction in radiation exposure to
the patient, surgeon, and surgical staff. Potential limitations
to our study include a single surgeon and single institution
cohort. However, we also believe that by having all cases
performed by a fellowship trained high volume surgeon and
senior resident, there was a reduction in variability of our
data. The surgeon and operating room staff were not able to
be completely blinded due to the inherent nature of surgical
intervention. However, our method is consistent with
previously published reports.9 Our cohort of 40, mostly
female and Caucasian patients, also limits applicability of
our results to a more diverse population. Although non-
obstructive urinary retention was considered in our
inclusion criteria, none of our patients in this small cohort
suffered from pure urinary retention and therefore our data
may not be reflective of this population subset. We also
used QoL questionnaires as surrogates for clinical out-
comes, which may not be ideal. There are also inherent
limitations associated with the ultrasound device, which we
tried to limit by using the same machine for all patients. Of
note, there was no additional cost in the use of ultrasound to
the patient at our institution. In addition, we realize the
shortcomings of not breaking down and further stratifying
fluoroscopy time based on different portions of the
procedure, but we believe that the ultimate goal of reducing
overall fluoroscopy time was addressed appropriately with
our design. Due to the limitations of our ultrasound device
and the InterStim leads, we were unable to compare
ultrasound alone to fluoroscopy as the deployment of the
leads still depends on the use of continuous fluoroscopy.
Further studies are needed to look at long term outcome, as
well as the learning curve associated with the use of
ultrasound.
5 | CONCLUSION
The use of ultrasound for safe placement of sacral neuro-
modulation leads results in reduction of radiation exposure to
the patient, surgeon, and operating room staff. Further studies
may be required to expand upon our findings. In the future,
with improvement in ultrasonographic technology and
echogenic needles and leads one may be able to perform
the entire procedure using ultrasound, eliminating the need
for fluoroscopy.
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